Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

As several pharma/biotech companies speed up efforts to make a vaccine for COVID-19, Novavax (NVAX) begins human testing of its candidate, NVX-CoV2373.

Coronavirus Vaccine Efforts Continue, Novavax Begins Human Trial

Novavax (NVAX) enrolls the first set of participants in a phase I/II clinical study for evaluating its coronavirus vaccine candidate, NVX-CoV2373.

Novavax Begins Clinical Study for Coronavirus Vaccine

Novavax's experimental COVID-19 vaccine has officially entered an early-stage trial.

Why Novavax Stock Is Skyrocketing  Today

AutoZone

Merck

S&P Set to Open Above 3000

Novavax Inc. (NASDAQ: NVAX) announced on Monday it had started the first phase of its novel coronavirus (COVID-19) vaccine trials.

Novavax Begins Phase 1 Clinical Trial Of Its Coronavirus Vaccine

Novavax said on Monday it has started the Phase 1 clinical trial of a novel coronavirus vaccine candidate and has enrolled the trial's first participants, with preliminary results slated for July.

Novavax starts Phase 1 clinical trial of coronavirus vaccine candidate

GAITHERSBURG, Md., May  25, 2020  (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced enrollment of the first participants in a Phase 1/2 clinical trial of its coronavirus vaccine candidate, NVX‑CoV2373, a stable, prefusion protein made using its proprietary nanoparticle technology. NVX‑CoV2373 includes Novavax’ proprietary Matrix‑M™ adjuvant to enhance immune responses and stimulate high levels of neutralizing antibodies. Preliminary immunogenicity and safety results from the Phase 1 portion of the trial are expected in July 2020.

Novavax Initiates Phase 1/2 Clinical Trial of COVID-19 Vaccine

Its lack of vaccine-development success stories makes its prospects for a COVID-19 vaccine dubious, but there are positive signs for investors.

Does Novavax Have What It Takes to Win the COVID-19 Vaccine Race?

Novavax Inc.’s (NASDAQ:NVAX) stock is a shadow of its former self, but shares did get a boost when the Gaithersburg, Maryland-based biotech recently received $384 million from a foundation to help the company develop a vaccine against Covid-19.

Novavax Hopes to Reverse Past Setbacks With Covid-19 Vaccine

The clinical biotech is benefiting from an analyst upgrade and optimism about its pipeline.

Why Novavax Is Blasting Higher Today

Global X Gold Explorers ETF

Invesco DWA Healthcare Momentum ETF

Amplify Junior Silver Miners ETF

Barclays Inverse US Treasury Composite ETN

Though last week was not upbeat for Wall Street, these ETFs breezed past Wall Street.

Wining ETF Areas of Last Week

Citigroup Glbl Underlying Tracker 2017-15.12.32 (Exp.08.12.32) on VS Dly 4XL USDvsGBP Series N

Direxion Daily Junior Gold Miners Index Bull 2X Shares

Direxion Daily S&P Biotech Bull 3X Shares

ProShares Ultra Bloomberg Crude Oil

These leveraged ETFs were outperformers last week.

Leveraged ETFs of Last Week

Moderna

The biotechnology companies creating COVID-19 vaccines should give hope to patients and investors. Moderna and Novavax are no exception.

Moderna and Novavax are Making Strides in Advancing Novel Coronavirus Vaccine Research

Novavax Secures COVID-19 Funding And Provides Additional Value With Eventual BLA Filing Of NanoFlu Vaccine

Novovax (NVAX) is set to receive funding of up to $388 million from CEPI to support clinical development and scaling up of production of its coronavirus vaccine candidate.

Novovax (NVAX) Surges on CEPI Funding for Coronavirus Vaccine

Gravity could kick in for this high-flying biotech stock. But, then again, it might not.

Is Novavax Stock Too Hot to Handle After Skyrocketing Over 900% This Year?

Uber

Aurora Cannabis

DraftKings

Uber, Novavax, DraftKings and Aurora Cannabis were our top stock trades for Wednesday. Let's have a look at what the charts say.

4 Top Stock Trades for Wednesday: UBER, ACB, NVAX, DKNG

Novavax (NVAX) news for Tuesday concerning funding for a vaccine to stop the novel coronavirus has NVAX stock rocketing higher.
The post Novavax News: NVAX Stock Skyrockets 79% on COVID-19 Vaccine Funding appeared first on InvestorPlace.

Novavax News: NVAX Stock Skyrockets 79% on COVID-19 Vaccine Funding

Novavax, Inc. (NASDAQ: NVAX) announced Monday after the close an award of an incremental $384 million in funding by the Coalition for Epidemic Preparedness Innovations alongside forecast-beating first-quarter results.

Novavax Analysts Say CEPI Funding 'Speaks Volumes' About Coronavirus Vaccine Development

Novavax received funding for the coronavirus vaccine and also delivered better-than-expected Q1 results resulting in a stock rally in yesterday's trading session.

Novavax Soars on Coronavirus Vaccine Funding: ETFs to Gain

Another $384 million in funding for its COVID-19 vaccine program gave the biotech a big shot in the arm.

Why Novavax Stock (NVAX) Is Skyrocketing Today

The big investment from CEPI will enable the biotech to fund clinical development of its COVID-19 vaccine candidate and rapidly scale up production.

Novavax's COVID-19 Vaccine Gets $388 Million in Funding, Biggest Amount Yet from CEPI

An epidemic preparedness foundation boosted its funding in coronavirus vaccine maker Novavax to $388 million, sending NVAX stock soaring Tuesday. But Novavax reported a Q1 loss.

Novavax Stock Rockets On Funding Boost For Coronavirus Vaccine

Novavax Inc. (NASDAQ: NVAX) shares jumped on Tuesday after the company announced that it would be receiving a sizable investment to further produce its COVID-19 vaccine.

Why This Funding Is Crucial for Novavax

Novavax Inc. NVAX, +70.57% shares rallied 45% in premarket trade Tuesday, extending after-hours gains from Monday, after the biotech company said it received a big investment for its COVID-19 vaccine candidate and topped Wall Street expectations for the quarter.

News for Novavax Stock (NVAX)